1610431-21-4
1610431-21-4
Chemical Structure
E104
- CAS No.: 1610431-21-4
- Formula:C21H23N5
- Molecular Weight:345.44
InChIKey: XURWVKISYBUGHB-UHFFFAOYSA-N
SMILES: NC1=NC2=C(C=CC=C2)C3=C1N=C(CCCC)N3CC4=CC=C(C=C4)N
Biological Activity: E104 is a selective Toll-like receptor 7 (TLR7) agonist. E104 promotes the release of pro-inflammatory factors and the polarization of macrophages toward the anti-tumor M1 phenotype by activating endosomal TLR7 and triggering downstream NF-κB and IRF signaling pathways. Antibody conjugates of E104 induce tumor regression. E104 can be used in research on pancreatic ductal adenocarcinoma and cancer[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
E104 | 99.38% | E104 is a selective Toll-like receptor 7 (TLR7) agonist. E104 promotes the release of pro-inflammatory factors and the polarization of macrophages toward the anti-tumor M1 phenotype by activating endosomal TLR7 and triggering downstream NF-κB and IRF signaling pathways. Antibody conjugates of E104 induce tumor regression. E104 can be used in research on pancreatic ductal adenocarcinoma and cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Greco I, et al. Characterization, mechanism of action and optimization of activity of a novel peptide-peptoid hybrid against bacterial pathogens involved in canine skin infections. Scientific reports. 2019 Mar 06;9(1):3679.
- [2]. Zhang A, et al. Nonglycosylated, Legumain-Cleavable ISACs Drive Potent Antitumor Immunotherapy via a Bystander Effect. Molecular cancer therapeutics. 2026 Apr 02;25(4):622-634. [Content Brief]
- [3]. Mullapudi MR, et al. Discovery of a novel Trop2-targeting immune-stimulating antibody conjugate with efficacy in pancreatic cancer models. Cancer Research. 2025 Apr 21;85(8_Supplement_1):5834-.
- [4]. DeYoung EG, et al. Synthesis and Optimization of 1-Substituted Imidazo[4,5-c]quinoline TLR7 Agonists. ACS Med Chem Lett. 2023 Sep 14;14(10):1358-1368. [Content Brief]
